logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Blackstone Announces the Launch of a New Company with Intellia Therapeutics and Cellex Cell Professionals GmbH

Blackstone Life Sciences, Intellia Therapeutics and Cellex Cell Professionals New Company Blackstone ( BX ) announced that funds managed by Blackstone Life Sciences have committed $250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor...

Read More

June 22, 2021

0

CureVac Has Very Interesting Future Plans

CureVac CureVac B.V. ( CVAC ) is a global biopharmaceutical company specializing in messenger RNA ( mRNA ) technology. The firm has more than 20 years of expertise in developing and optimizing versatile biological molecules for prevention and treatment purposes....

Read More

March 22, 2021

0

The Market Rebounding That Left Important Biotechnology Firms Behind

COVID-19, The Market Rebounding and the Biotech Firms That Did and Didn't Rally The Market Rebounding included: Amgen ( AMGN ) , Biogen ( BIIB ) and Incyte ( INCY ); t he only biotechnology firms to rebound in early...

Read More

March 13, 2020

0

Negative News from Ionis Pharmaceuticals Phase 3 Trial for Huntington's Disease. Good News from the Regeneron Antibody Cocktail for COVID-19

Negative News from Ionis Pharmaceuticals  Ionis Pharmaceuticals ( IONS ) announced that its partner, Roche ( RHHBY ) , has decided to discontinue dosing in the Phase 3 GENERATION HD1 study of tominersen for Huntington's disease (HD). A pre-planned review...

Read More

March 23, 2021

0

Halozyme Therapeutics Good News About Approvals. See Also: Arrowhead Pharmaceuticals Good Trial Results for Liver Diseases  

Halozyme Therapeutics Approvals for DARZALEX ® SC Halozyme Therapeutics ( HALO ) announced that the European Commission ( EC ) has granted Janssen Pharmaceutical Companies of Johnson & Johnson two marketing authorizations for the subcutaneous formulation of daratumumab, known as...

Read More

June 23, 2021

0

Vir Biotechnology: Promising Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 for Chronic HBV Infection  

Vir Biotechnology Announced Positive Safety Findings from its Ongoing Trials for Chronic HBV Vir Biotechnology ( VIR ) announced new data from its ongoing Phase 2 clinical trials of VIR-2218 and ongoing Phase 1 studies of VIR-3434 in patients with...

Read More

June 25, 2021

0

Good News for Exelixis and for Japanese Renal Cell Carcinoma Patients

Exelixis, Takeda and Japanese RCC Patients Today we learned from Exelixis ( EXEL ) that Takeda Pharmaceutical Company Limited , which is responsible for the clinical development and commercialization of Exelixis' oncology drug   CABOMETYX® (cabozantinib) in Japan, informed that...

Read More

March 25, 2020

0

Why We Are Still Optimistic. See Also: Inovio's Good News

COVID-19 and the Nation's Hospitals Disagreeable news with regard to the nation's hospitals is their unpreparedness to face a sudden crisis, let alone an unexpected and unprecedented pandemic. The system the hospitals are running on has been causing problems for...

Read More

March 27, 2020

0

IVERIC bio Receives FDA Agreement Under an SPA for GATHER2 Phase 3 Clinical Trial of Zimura®

IVERIC bio GATHER2 Trial of Zimura® for Geographic Atrophy  IVERIC Bio ( ISEE ) announced that it received written agreement from the U.S. FDA under a Special Protocol Assessment ( SPA ) for the overall design of GATHER2, the pivotal...

Read More

July 6, 2021

0

Illumina Acquisition of GRAIL: A Challenging Story That Boosted ILMN's Stock Price

Illumina Acquisition of GRAIL On September 21, 2020 , Illumina and GRAIL Inc. announced that they entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion, upon closing of the transaction. On...

Read More

March 31, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 114
  • 115
  • 116
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy